 If you are enrolled in Phase 1, the combination dose of ixazomib, gemcitabine, and doxorubicin you receive will depend on when you join this study. The first group of participants will receive the lowest combination dose level. Each new group will receive a higher dose of the drug combination than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of the drug combination is found. 